TREAT YOUR ELIGIBLE PATIENTS WITH SIMPLICITY

Extend to Q16 dosing directly after only 3 loading doses in both nAMD and DMO with EYLEA 8 mg

^[1]

The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.^[1]

Dosing diagram for illustrative purpose only.

After reaching Q16, patients can be extended to Q20 using an extension method such as T&E*

The frequency of monitoring visits should be based on the patient’s status and at the physician’s discretion.^[1]

Dosing diagram for illustrative purpose only.

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.^[1]

The recommended dose is 8 mg aflibercept, equivalent to 0.07 mL solution. The posology is the same for the nAMD and DMO indications. The 8 mg dose requires use of the EYLEA 114.3 mg/ml vial.^[1]

EYLEA at monthly doses of 8 mg has not been studied for more than 3 consecutive doses.^[1]

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).^[1]

Abbreviations

DMO, diabetic macular oedema. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q8, every 8 weeks. Q12, every 12 weeks. Q16, every 16 weeks. Q20, every 20 weeks. T&E, treat and extend. VEGF, vascular endothelial growth factor.